GlassScriptPhysician profile
Angelle Williams
NPI 1104551225
$2,943.22
in general payments reported to CMS, 2019-2025
30 companies · $1,437 in 2025
The $1,437 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $388 · 2024: $1,118 · 2025: $1,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,943.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $585.99 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $451.98 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $367.99 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $204.74 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $193.02 | 2023-2025 | Rybelsus, Wegovy, Ozempic |
| Otsuka America Pharmaceutical, INC. | $180.48 | 2023-2025 | Rexulti |
| Viiv Healthcare Company | $122.11 | 2023 | Cabenuva |
| Axsome Therapeutics, INC. | $78.06 | 2024-2025 | Auvelity |
| Dexcom, INC. | $75.89 | 2024-2025 | Dexcom G6 Transmitter |
| Ardelyx, INC. | $71.08 | 2024 | Ibsrela |
| Vanda Pharmaceuticals INC. | $68.07 | 2025 | Fanapt |
| Glaxosmithkline, LLC. | $48.79 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.75 | 2024-2025 | Xifaxan |
| Cequr Corporation | $46.43 | 2024-2025 | Cequr Simplicity |
| Organon LLC | $45.86 | 2023 | Nexplanon |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $41.49 | 2024-2025 | Eliquis, Camzyos |
| Theratechnologies INC. | $36.80 | 2023 | Trogarzo, Egrifta |
| Insulet Corporation | $34.64 | 2024-2025 | Omnipod |
| Merck Sharp & Dohme LLC | $30.51 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Amgen INC. | $28.38 | 2024 | Otezla, Repatha |
| Abbott Laboratories | $25.22 | 2025 | Freestyle Libre 3 |
| Ironwood Pharmaceuticals, INC | $21.32 | 2024 | |
| Abiomed | $20.35 | 2025 | |
| Exact Sciences Corporation | $19.92 | 2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $18.14 | 2025 | |
| Dynavax Technologies Corporation | $17.55 | 2025 | Heplisav-B |
| Biogen, INC. | $16.44 | 2025 | Skyclarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.58 | 2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $14.56 | 2025 | Zoryve |
| Vertex Pharmaceuticals Incorporated | $14.08 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angelle Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.